Product Information
PROMETHAZINE 12.5 MG SUPPOS is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $1.8542 per EA under NDC 45802075830. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 30, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5 mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802075830
Classification
Generic
Dosage Form
SUPPOSITORY
Route
RECTAL
Effective Date
9/23/2026
Active Ingredients
PROMETHAZINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA040500FDA Approved
6/30/2003
TE Code
AB
On Market Since
6/27/2006
Pharmacological Classes
Price Statistics
The NADAC for PROMETHAZINE 12.5 MG SUPPOS has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 80.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8542 per EA |
|---|---|
| All-time high | $10.4335 (Jul 15, 2015) |
| All-time low | $1.6445 (Nov 20, 2024) |
| 52-week high | $2.1630 |
| 52-week low | $1.7078 |
| Median price | $5.2565 |
| Average price | $5.5771 |
| Largest weekly change | +60.0% (Jan 18, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Promethazine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phenothiazine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PROMETHAZINE 12.5 MG SUPPOS?
The current National Average Drug Acquisition Cost (NADAC) for PROMETHAZINE 12.5 MG SUPPOS, manufactured by Padagis Israel Pharmaceuticals Ltd, is $1.8542 per EA (NDC 45802075830), effective Sep 30, 2026.
How has the price of PROMETHAZINE 12.5 MG SUPPOS changed over time?
Over the history we have for it, the NADAC for PROMETHAZINE 12.5 MG SUPPOS has declined 80.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PROMETHAZINE 12.5 MG SUPPOS?
Since Nov 28, 2013, the NADAC for PROMETHAZINE 12.5 MG SUPPOS has ranged from a low of $1.6445 (Nov 20, 2024) to a high of $10.4335 (Jul 15, 2015), with a median of $5.2565 per EA.
Are there cheaper alternatives to PROMETHAZINE 12.5 MG SUPPOS?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PROMETHAZINE 12.5 MG SUPPOS in a comparable dosage form, but none are currently priced below it.
Who manufactures PROMETHAZINE 12.5 MG SUPPOS?
PROMETHAZINE 12.5 MG SUPPOS (NDC 45802075830) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.